Factor IX Dosing
Factor IX dosing uses the patient’s weight and product-specific recovery to calculate the IU needed to reach a target FIX activity level.
Indications for Use
Used for hemophilia B to treat acute bleeds, provide peri‑procedural coverage, and for routine prophylaxis to maintain FIX troughs and prevent arthropathy. Dosing targets FIX activity (e.g., ~1 IU/kg ≈ 1% rise). Extended‑half‑life products lower infusion frequency and improve bleed prevention (phase 3 trials: rIX‑FP and rFIXFc showed sustained higher FIX levels and reduced annualized bleed rates 1; 2).
Insights & Cautions
Target 1 IU/dL rise per ~1 IU/kg with standard FIX; extended‑half‑life products need less frequent dosing. For prophylaxis, weekly 40 IU/kg or q14 days 75 IU/kg maintains troughs 12–20 IU/dL and yields ABR ≈0 1 [Level I evidence]. rFIXFc allows weekly–q14‑day dosing with similarly low ABR 2 [Level I evidence]. Cautions: inter‑patient PK variability, breakthrough bleeds at adequate plasma levels, and rare inhibitor formation.